Clinical Trials | June 12, 2022
Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Amarex Clinical Research guides its client to phase II of FDA trials
Amarex Clinical Research guides its client to phase II of FDA trials
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated
